Chairpersons

John William Eikelboom (Hamilton, Canada)

Dominick Joseph Angiolillo (Jacksonville, United States of America)

Subtitle

Sponsored by Boehringer Ingelheim

Learning objectives

Describe the latest data on non-Vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation requiring ablation or percutaneous coronary intervention (PCI). Apply practical guidance on dual versus triple antithrombotic therapy.

Presentations

Setting the scene: safety, efficacy, and reversal.

Speaker: John William Eikelboom (Hamilton, Canada)

 

Finding order in complexity: dual versus triple antithrombotic therapy post-PCI.

Speaker: Dominick Joseph Angiolillo (Jacksonville, United States of America)

 

Antithrombotic therapy post-PCI: applying evidence from RE-DUAL PCI to challenging cases.

Speaker: Jurrien M ten Berg (Nieuwegein, Netherlands (The)

 

Practical tips on uninterrupted NOACs in atrial fibrillation ablation.

Speaker: Dhiraj Gupta (Liverpool, United Kingdom of Great Britain & Northern Ireland), John William Eikelboom (Hamilton, Canada)

 

Panel discussion and audience questions: NOACs in cardiology settings.

Speaker: John William Eikelboom (Hamilton, Canada), Dominick Joseph Angiolillo (Jacksonville, United States of America)